Ten ewe lambs (approximately 40 kg) were used to determine the influence of prostaglandin E 1 (PGE1) and synthetic somatotropin-release inhibiting factor (SRIF) on plasma levels of ovine growth hormone (GH), prolactin (PRL) and thyrotropin (TSH). Intravenous injection of PGE1 (20 and 100/ag/kg) stimulated a dose-related increase in plasma levels of GH (20 + 6 and 50 + 10 ng/ml), respectively. Intravenous injection of SRIF (500 ~g), significantly (P<.05) depressed the GH stimulation by PGE 1 (20/2g/kg), while lower doses (5 and 50 /lg) were ineffective. The highest dose of PGE 1 (100/2g/kg) also stimulated a significant (P<.01) increase in plasma levels of PRL. One and 10/~g doses of PGE1/kg had no influence, while the 20 #g/kg dose appeared to stimulate PRL secretion although the response was quite variable. Treatment with SRIF (500 ~tg) significantly (P<.05) reduced the PRL stimulation by PGEI at 20 /.tg/kg. However the variable PRL response to the 20/2g/kg dose of PGE 1 makes this observation inconclusive. Neither PGE 1 nor SRIF exerted an influence on plasma TSH.
INTRODUCTION
Prostaglandin E 1 (PGE 1) has been reported to be stimulatory to GH secretion in vivo in both sheep (Hertelendy et al., 1972) and humans (Ito et al., 1971) . Other workers have reported that PGE 1 injected intraventricularly stimulates PRL release in the rat (Harms et al., 1973) . A stimulation of TSH release from rat pituitaries incubated in vitro has also been reported (Dupont and Chavancy, 1972; Vale et al., 1971) .
It has been previously reported that synthetic somatostatin (500/ag) (Somatotropin-release inhibiting factor or SRIF) is inhibitory to the stimulation of ovine growth hormone (GH) by arginine (Davis, 1975) . Others have reported that varying doses of SRIF are inhibitory to the secretion of GH in rats and humans (Vale et al., 1973; Siler et al., 1973; Parker et al., 1974; Brazeau et al., 1974) . An in vivo effect of SRIF on the secretion of prolactin (PRL) has not been conclusively demonstrated, although an inhibitory influence of SRIF on basal PRL release from rat anterior pituitary cells in vitro has been reported (Vale et al., 1973) .
The present series of experiments were designed to determine the dose-response influence of intravenously injected PGE 1 on the 172 JOURNAL OF ANIMAL SCIENCE, Vol. 41, No. 1, 1975 1 73 secretion of GH, PRL and TSH, and to examine the effect of varying doses of SRIF on the stimulation of GH secretion by PGE1.
EXPERIMENTAL METHODS
Ten ewe lambs (approximately 40 kg), five control and five treatment were used for study 1 and 2. The experiments were conducted over 1 month, with one dose of PGE1 and/or SRIF at 4-day intervals. Permanent indwelling jugular catheters (polyvinylchloride tubing) were inserted 1 day prior to the first experiment and were kept patent throughout the 4-week period by flushing daily with sterile heparinized saline.
Study 1. Dose-Response Effect of PGE 1 on GH, PRL and TSH. In the first experiment, a dose of 1/lg PGE 1/kg body weight was injected iv. Blood samples were obtained at 15-rain intervals for 1 hr prior to injection and for 2 hr post-injection. In the subsequent 2 experiments, PGE 1 doses of 10/2g/kg and 100/2g/kg were injected. The blood sampling schedule was the same as that in experiment 1.
Study 2. Dose-Response of SRIF on GH and PRL Response to PGE 1. In a series of three experiments, the lambs were injected with PGE1 at 20 pg/kg (control) or PGE 1 (20/~g/kg) + SRIF at 5, 50 and 500 micrograms. All treatments were administered by single injection into an indwelling jugular cannula. Blood samples were obtained (via jugular cannula) at 15-min intervals for 1-hr pre-injection and for 2-hr post-injection.
In all experiments, the blood samples were placed on ice immediately after collection and were then refrigerated overnight before the plasma was collected and frozen. Plasma levels of GH, PRL and TSH were determined by radioimmunoassay methods which have been previously reported (Davis et al., 1971; Davis, 1972; Borger and Davis, 1974) .
Study 3. PGE l (20 #g/kg) and SRIF (I0 I.tg intracarotid) on GH and PRL.
This study was conducted to obtain further information on the influence of small doses of SRIF on the GH response to PGE l and the PRL response to the 20 /2g/kg dose of PGE 1. In this study the carotid arteries on one side of the neck of seven wether lambs (50 to 60 kg) were placed surgically into a loop of skin as described by Bone et al. (1962) . This carotid loop was used for the injection of SRIF. A polyvinyl catheter was inserted into the contralateral jugular vein the day before the experiment. Three lambs received a control injection of PGE 1 (20/~g/kg) intravenously and the treated lambs (four) were injected iv with PGE 1 (20 #g/kg) and intracarotidly with SRIF (10 #g). Blood samples were obtained from the jugular catheters at 15-min intervals for 1 hr before and 2 hr after treatment.
The data were analyzed statistically using Student's t to test the difference between treatment means at time of maximal response. Figure 1 . Plasma levels of GH after the intravenous injection of saline (o-o) or PGE 1 (e--e) at 1, 10, and 100 vg/kg. Each point represents the mean -+ standard error of the mean (SEM) of five observations. DAVIS AND ANFINSON of PGE 1 (1 and 10/lg/kg) significantly affected plasma levels of GH (figure 1). The highest dose (100 /~g/kg) increased (P<.001) plasma GH within 15 min, and the maximum response was observed 30-min post-injection (figure 1).
Plasma PRL. Similarly, plasma levels of PRL were not influenced by the injection of PGE l at 1 or 10 gtg/kg but there was a significant (P<.001) increase in plasma PRL after the injection of 100 pg of PGE t/kg (figure 2).
Plasma TSH. None of the doses of PGE 1 used in the present experiment were effective in changing plasma levels of TSH (table 1) . Plasma GH. The 20 /ag/kg dose of PGE 1 stimulated increased plasma levels of GH over pre-injected levels in all three studies (figure 3). The GH response to PGE 1 stimulation was decreased (P<.01) 15 min after injection of 500 gtg of SRIF. In contrast, plasma levels of GH appeared to be greater (not statistically significant) following injection of either 5 or 50/lg of SRIF -+ PGE 1 than plasma GH after PGE 1 treatment alone ( figure 3) .
Plasma PRL. Injection of .20 /.tg PGE]/kg was not as effective in stimulating increased plasma PRL levels (figure 4) as with GH. Plasma PRL levels following this dose of PGE 1 were significantly (P<.05) greater than pre-injection levels only in the third experiment (PGE 1 + 500 gtg SRIF) (figure 4). The simultaneous treatment with 500 gtg of SRIF significantly (P<.05) reduced the PRL response to PGE 1 (figure 4). Plasma levels of PRL were not significantly influenced by injection of either 5 or 50 ttg of SRIF. This study was conducted in view of the suggested stimulatory influence of low doses of SRIF on GH (study 2) and the variable PRL response to PGE 1 at 20/~g/kg. As observed in the previous experiments, PGE l (20 /~g/kg) stimulated a significant (P<.01) increase in plasma levels of both GH and PRL as compared to preinjection levels (figure 5). In contrast to the results obtained in study 2, 10 ~g of SRIF injected intracarotidly did not enhance the GH response to PGE 1 but inhibited this response (P<.05). The stimulatory effect of PGE l on plasma PRL was not influenced by 10 /~g of SRIF.
Discussion
The stimulatory influence of PGE 1 on GH secretion is in agreement with previous reports that PGE1 is capable of stimulating an increase in plasma levels of GH in sheep (Hertelendy et al., 1972) and humans (Ito et al., 1971) . In addition the report that PGEI is capable of stimulating GH release from rat pituitaries incubated in vitro (Schofield, 1970; MacLeod and Lehmeyer, 1970; Hertelendy, 1971; Hertelendy et al., 1971) would suggest that PGE] exerts this stimulatory effect directly at the level of the pituitary.
Our results also suggest that PGEI is a more potent stimulus to GH secretion than to PRL. This suggestion is based upon the observation that the 20 gtg/kg dose of PGE 1 consistently stimulated increased plasma GH, but not PRL. However this evidence is not conclusive since the inability to detect increased plasma PRL may be due to the greater variability of plasma PRL levels than those observed for GH. The observation that PGE 1 is capable of stimulating increased plasma PRL is in agreement with the previous data reported by Harms et al. (1973) , who observed an increase in plasma PRL in the rat following the injection of PGE 1 (2 gtg/kg) into the third ventricle. However these workers did not observe an effect of PGE 1 on PRL secretion when injected directly into the pituitary. It is entirely possible that the higher levels of PGE 1 were capable of influencing the secretion of PRL in our studies by exerting a hypothalamic influence on the release of either prolactin inhibiting factor (PIF) or a prolactin releasing factor (PRF).
The inability to influence plasma levels of TSH by any of the doses of PGE 1 are not in agreement with previous reports that PGE 1 stimulates the release of TSH from rat pituitaries in vitro (Vale et al., 1971; Dupont and Chavancy, 1972) . However Thompson et al. (1974) have reported that the intrapituitary injection of PGE 1 potentiated the TRH induced rise in TSH secretion but was ineffective on basal TSH secretion in rats. To date we have not examined the influence of PGE 1 on the TSH response to TRH in the sheep, but our data on the lack of an effect of PGE 1 on the basal levels of TSH are in agreement with those of Thompson et al. (1974) .
The present data on the inhibitory influence of SRIF on the PGE 1 stimulation of GH further extends the results of previous reports. It has been previously observed that SRIF is inhibitory to the arginine stimulation of GH secretion in sheep (Davis, 1975) and humans (Siler et al., 1973) . SRIF has also been reported to exert an inhibitory effect on both pentobarbital stimulated GH and resting GH levels in rats (Brazeau et al., 1974) .
